Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611572 · ClinicalTrials.gov registry record · Phase 1
GABA-glutamate Interactions and Psychosis
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00611572 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 23 participants.
The verdict
NCT00611572, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy volunteers.
Interventions
- DRUG iomazenil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-01 |
| Est. Completion | 2018-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00611572
The ClinicalTrials.gov registry entry for NCT00611572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which iomazenil is the first listed.
NCT00611572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00611572 about?
NCT00611572 is a clinical study titled "GABA-glutamate Interactions and Psychosis". This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy volunteers.
What is the current status of trial NCT00611572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2007-01. Estimated completion is 2018-10-02.
What interventions are being tested in trial NCT00611572?
The interventions under investigation include: iomazenil (DRUG).
Who is sponsoring clinical trial NCT00611572?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.